IP Library Granted Patent US 7,666,833
Granted Patent B2
US 7,666,833 · App. 11/756,456 · Granted Feb 23, 2010

Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,666,833
App. No.
11/756,456
Granted
Feb 23, 2010
Kind
B2
Abstract

The present invention relates to compositions containing unacylated ghrelin and derivatives thereof and their uses in the control of glycemia in ageing patients, GH deficient patients, diabetic patients and obese patients.

Claims (12)

1. A method for treating a metabolic disorder associated with elevated glucose level in a patient comprising administering a therapeutically effective amount of an agent selected from the group consisting of (a) unacylated ghrelin; (b) the unacylated ghrelin of (a) having one or more conservative amino acid substitutions; and (c) pharmaceutically acceptable salts of (a) or (b), to said patient.

2. The method of claim 1 , wherein the elevated glucose level results from cortisol excess.

3. The method of claim 1 , wherein the elevated glucose level is associated with dyslipidemia.

4. The method of claim 3 , wherein the dyslipidemia is excess free fatty acids.

5. The method of claim 3 , wherein the dyslipidemia is excess triglycerides.

6. The method of claim 1 , wherein the metabolic disorder is a metabolic syndrome.

7. The method of claim 1 , wherein the metabolic disorder is associated with death of insulin-secreting cells.

8. The method of claim 7 , wherein the insulin-secreting cells are pancreatic β cells.

9. The method of claim 1 , wherein the metabolic disorder is type I diabetes.

10. The method of claim 1 , wherein the metabolic disorder is type II diabetes.

11. The method of claim 1 , wherein treatment of the metabolic disorder associated with elevated glucose level is through enhancement of proliferation or of survival of insulin-secreting cells.

12. The method of claim 11 , wherein the enhancement of proliferation or of survival of insulin-secreting cells is achieved by the administration of the agent to the patient.

Assignments (2)
CHANGE OF ASSIGNEE ADDRESS Recorded Jul 13, 2009
From: ALIZE PHARMA SAS
To: ALIZE PHARMA SAS
Reel/Frame 022939/0431 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2007
From: GHIGO, EZIO; VAN DER LELY, AART JAN
To: ALIZE PHARMA SAS
Reel/Frame 019710/0958 →